Health ❯ Healthcare ❯ Patient Care

Cancer Treatment

Breast Cancer Chemotherapy Survival Rates Support Systems Immunotherapy Relapse Prevention Metastatic Cancer Metastatic Breast Cancer Routine Check-ups Exercise Therapy Survival Prediction Facial Analysis Tools Early Detection Pediatric Cancer Emergency Services EGFR Mutations Treatment-naïve Patients Preventive Strategies Wellbeing Centers Hair Restoration Methods Impact of Stress on Health Oncological Services Clinical Research Prostate Cancer Palliative Care Patient Preferences Nurse Preparedness Adverse Effects Royal Engagements Relapsed/Refractory CLL/SLL Non-Small Cell Lung Cancer Drug Development Platinum-Resistant Cancer Response Rates Support Services Relapsed/Refractory Multiple Myeloma Liver Cancer Side Effects Advanced Prostate Cancer Progression-Free Survival ALK-positive NSCLC Community Impact Acute Myeloid Leukemia T-cell Therapy Oncologist Consultation Trial Outcomes Advanced Cancer Therapies Triple-Negative Breast Cancer Monitoring King Charles III Early Stage Treatment Royal Marsden Hospital

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Results presented at SABCS, published in JCO, show a clinically meaningful delay in progression with first-line maintenance tucatinib.

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

County Durham Trust Sets Out Reforms After Review Exposes Decade of Breast Surgery Failures

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

UCLA Study Links Inflammation to Specific Fatigue Types After Early-Stage Breast Cancer Treatment

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Study Finds Many Advanced Cancer Patients Get Unwanted Life‑Extending Care

Teddi Mellencamp Reports Removal of New Abnormal Skin Spot for Testing